Alpha Cognition’s Strong Financial Performance and Promising Alzheimer’s Treatment Drive Buy Rating

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Alpha Cognition Inc (ACOG – Research Report), retaining the price target of $20.00.

Ram Selvaraju has given his Buy rating due to a combination of factors including Alpha Cognition’s recent financial performance and promising product launch. The company reported higher-than-expected net sales for the first quarter of 2025, prompting an upward revision of sales forecasts for the full year. This strong financial performance, coupled with a narrower net loss than anticipated, indicates robust business fundamentals.
Furthermore, the launch of ZUNVEYL, a treatment for Alzheimer’s disease, has shown early positive results. The product has received favorable feedback from healthcare providers, with a significant portion already prescribing it and no major adverse effects reported. The ease of obtaining prior authorizations and the availability of the drug in multiple doses nationwide further support its commercial potential. Additionally, Alpha Cognition’s solid cash position is expected to sustain its operations for the next two years, underpinning the company’s growth prospects.